Compare Adaptive Biotechnologies Corp (ADPT) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Northrop Grumman Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Northrop Grumman Corporation trades at $544.26 (market cap $77.98B). The key difference: Northrop Grumman Corporation is far larger — about 23.4× Adaptive Biotechnologies Corp's market cap, and Northrop Grumman Corporation pays a 1.71% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | NOC | |
|---|---|---|
Market Cap | $3.33B | $77.98B |
Sector | Health | Industrials |
52-Week High | $22.37 | $768.02 |
52-Week Low | $10.24 | $496.02 |
Enterprise Value | $3.19B | $92.21B |
Dividend Yield | — | 1.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Northrop Grumman (NOC) trades at $549.04, showing minimal daily movement. The stock exhibits a bullish technical trend, supported by strong fundamentals including a 10.8% net income margin and consistent earnings beats. Recent news highlights contract wins and positive defense sector sentiment. Analyst consensus is strongly bullish with a $694.40 price target, indicating significant upside potential from current levels.
The outlook remains positive given the company's $95.61B backlog and stable cash flow generation. Key risks include political budget uncertainty and execution challenges. With solid institutional support and improving profitability metrics, NOC presents a compelling opportunity for investors seeking defense sector exposure, though geopolitical developments require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
